MedTrace Logo

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

NCT01825330 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2016-03-31

No results posted yet for this study

Summary

The study tests the effect of the NeuroAD on Alzheimer patients' cognitive function. The NeuroAD uses non-invasive stimulation of both magnetic and cognitive training.

Conditions

Interventions

DEVICE

TMS and cognitive stimulation

Synchronized TMS and cognitive stimulation to 6 brain areas.

DEVICE

sham

Sponsors & Collaborators

  • Neuronix Ltd

    lead INDUSTRY

Principal Investigators

  • Charlie Bernick, MD · Lou Ruvo Brain Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-01-31
Completion
2016-03-31

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01825330 on ClinicalTrials.gov